SHANGHAI PHARMACEUTICALS HOLDING CO., LTD

Shanghai Pharmaceuticals Holding Co., Ltd

601607

CNE000000C82

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 15/07/2024 BST			5-day change	1st Jan Change
19.28 ^CNY	+0.36%		+0.57%	+15.24%

07-04	Shanghai Pharmaceuticals Gets Nod to Register Ezetimibe Tablets	MT
06-28	Shanghai Pharmaceuticals Holding Co., Ltd Announces Final Dividend for the Year Ended 31 December 2023, Payable on 27 August 2024	CI

Shanghai Pharmaceuticals Holding Co., Ltd.(SHSE:601607) added to Shanghai Stock Exchange Health Care Sector Index

January 03, 2017 at 05:00 am

Shanghai Pharmaceuticals Holding Co., Ltd. has been added to Shanghai Stock Exchange Health Care Sector Index.

Latest news about Shanghai Pharmaceuticals Holding Co., Ltd

Shanghai Pharmaceuticals Gets Nod to Register Ezetimibe Tablets	07-04	MT
Shanghai Pharmaceuticals Holding Co., Ltd Announces Final Dividend for the Year Ended 31 December 2023, Payable on 27 August 2024	06-28	CI
Shanghai Pharmaceuticals Holding Co., Ltd Announces the Appointment of Zhang Wenxue as Non-Executive Director and Member of the Strategy Committee	06-28	CI
Shanghai Pharmaceuticals Holding Co., Ltd Announces Resignation of Chen Fashu as Non-Executive Director	05-27	CI
Shanghai Pharma Gets Clinical Trial Approval for Antidepressants	05-27	MT
Shanghai Pharmaceuticals' Unit Gets Nod for Raw Drug Material for Hypertension, Heart Disease; Shares Down 3%	05-21	MT
Shanghai Pharmaceuticals Unit Gets Green Light to Market Cancer Drug	05-14	MT
Shanghai Pharmaceuticals Gets Regulatory Nod to Trial Tumor Drug	05-14	MT
Shanghai Pharmaceuticals Holding's Q1 Profit Rises 2% as Revenue Grows 6%	04-29	MT
Shanghai Pharmaceuticals Holding Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Shanghai Pharma's Profit Plunges 33% in 2023 Despite 12% Revenue Growth; Shanghai Shares Rise 4%	04-01	MT
Shanghai Pharmaceuticals Holding Co., Ltd Proposes Final Dividend for the Year Ended 31 December 2023	03-28	CI
Shanghai Pharmaceuticals Holding Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Shanghai Pharmaceuticals Gets Nod to Register Amiodarone Hydrochloride Injection	03-22	MT
Shanghai Pharma Names Chairman; Vice Chairman Resigns	03-20	MT
Shanghai Pharmaceuticals Holding Co., Ltd Announces Executive Changes	03-19	CI
Shanghai Pharma Unit's Citicoline Sodium Injection Passes Regulatory Evaluation	03-08	MT
Shanghai Pharmaceuticals Holding Co., Ltd Announces Change of Principal Place of Business in Hong Kong	02-20	CI
Shanghai Pharma Receives Approval For New Dosage of Leukemia Drug	02-13	MT
Shanghai Pharma, Yunnan Baiyao Renew Sales, Procurement Deal	12-22	MT
Shanghai Pharmaceuticals Holding Co., Ltd Announces Change of Joint Company Secretary	12-21	CI
Shanghai Pharmaceuticals Holding Gets Fine for Anti-Monopoly Violations	12-18	MT
China Aproves Phase 1 Clinical Trial of Shanghai Pharma Subsidiary's Capsule for Tumors	12-08	MT
Shanghai Pharma's Ex-Vice President Becomes Sixth Senior Exec to Face Probe	11-23	MT
Shanghai Pharmaceuticals Chairman Steps Down	11-20	MT

Chart Shanghai Pharmaceuticals Holding Co., Ltd

Duration

Period

Chart Shanghai Pharmaceuticals Holding Co., Ltd

More charts

Shanghai Pharmaceuticals Holding Co Ltd is a China-based company principally engaged in pharmaceutical industry, distribution and retail business. The Company's products include innovative drugs, chemical drugs, traditional Chinese medicines and rare disease drugs. The Company's products are mainly used in the cardiovascular system, digestive tract and metabolism, systemic anti-infection, central nervous system, anti-tumor and immunomodulators, musculoskeletal system and respiratory system. In addition, the Company also provides medical logistics and warehousing services. The Company distributes its products both in the domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

29/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Shanghai Pharmaceuticals Holding Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.28 CNY

Average target price

20.67 CNY

Spread / Average Target

+7.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+15.24%	8.76B
MCKESSON CORPORATION	+26.13%	75.74B
CARDINAL HEALTH, INC.	-5.35%	23.24B
SINOPHARM GROUP CO. LTD.	-6.70%	7.68B
HUADONG MEDICINE CO., LTD	-33.02%	6.69B
H. LUNDBECK A/S	+20.21%	5.58B
GALENICA AG	+3.23%	4.22B
EBOS GROUP LIMITED	-3.66%	3.99B
MEDIPAL HOLDINGS CORPORATION	+14.24%	3.39B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+8.74%	3.23B

Pharmaceuticals Wholesale